In this report we've compared the plasma protein profiles of 4 individuals in a family. Father and the younger son both are hemoglobin (Hb) Eb-thalassemic {Cod 26 (G-A)/IVS 1-5 (G-C)}, but the father never requires transfusion, whereas the younger son requires monthly blood transfusion. Mother and the elder son are HbEE {Cod 26 (G-A)/Cod 26 (G-A)} without any history of transfusion. Proteomic study was done on the plasma fraction of the blood following ammonium sulphate precipitation. Proteins were separated by 2D-gel electrophoresis, expression of proteins compared by densitometry and proteins identified by tandem MALDI mass spectrometry. Proteins responsible in hemolysis, hypercoagulation and hemoglobin scavenging have shown differential regulation, establishing the relation between the differences in the levels of plasma proteins with the progression of the disease phenotype, manifested in the extent of transfusion dependence of the patient.
Introduction
The hemoglobin (Hb) E-b is one of the commonest forms of hemoglobinopathies worldwide. 1 The HbE mutation is located near the junction between the first exon and the first intron of the b-chain gene. Nucleotide sequence change near the consensus splice site region activates a cryptic splice site, which is not normally used for mRNA processing. This new splice site competes with the normal splice site. Some mRNAs are still processed using the normal splice site and thus produce a protein with a Lys instead of a Glu at position 26. The variant (HbE) is thus innocuous in its heterozygous and homozygous states. 2 The primary clinical importance of HbE trait arises when the b E allele interacts with other b-thalassemia mutations leading to a moderate to severe anemia known as HbEb-thalassemia. 3 In this paper we are presenting a classical case which shows that, not only different b-thalassemia mutations can give rise to variety of clinical consequences, but also same b-thalassemia mutation upon interacting with b E allele can lead to variety of clinical manifestation of the disease condition. Here, two members of the family (the father and the younger son) even after having identical b chain mutation, shows marked difference in terms of clinical severity and transfusion requirement.
Materials and Methods
We describe clinical details of a thalassemic family showing an unusual and interesting pattern of blood transfusion requirement between two members of identical b globin mutational background. In the family, the father (P1, Table 1 ) is HbE-b-thalassemic with no history of blood transfusion. Though his hemoglobin was found to be less than normal (6.8 g/dL) never experienced any clinical complications and physiological manifestation of anemia, even after doing vigorous physical work. Mother (P2, Table 1 ) is HBEE and has no history of blood transfusion. Elder son (P3, Table 1 ) is also HbEE, like mother and never had blood transfusion. As per classical symptoms of HbEE patients, the mother (P2) and the elder son (P3) both maintain good hemoglobin level and are asymptomatic in terms of expression of anemic features. Younger son (P4 , Table 1 ), is HBE-b thalassemic like his father, however, is highly anemic and requires monthly blood transfusion, starting from an age of 8 months. We have also included a nonrelated HbE-b thalassemic sample (P5) having similar clinical features as that of the P4 to validate or confirm the plasma proteome of P4.
Peripheral blood samples were collected from every member of the above-mentioned family, patient and normal volunteers in vials containing 5 mM ethylenediaminetetraacetic acid. Written consent was taken from adults and in case of children it was taken from the parents as per guidelines of institutional ethical committee. The handling of all human blood samples was carried out in accordance with the guidelines established by the Local Ethical Committee. For the patients P4 and P5 who are on regular blood transfusion, peripheral blood was taken after transfusion gap of 45 days, the maximum gap they could withstand. Plasma and red blood cells were separated using 75% percoll for the proteomic studies, as described earlier. 4 As per protocol all members of the affected family were evaluated for baseline clinical investigations, which are as follows: fetal hemoglobin (HbF), HbA 0 , HbA 2 , hemoglobin, mean cell volume, mean cell hemoglobin, mean cell hemoglobin concentration, red cell distribution width and hematocrit. The hematologic data (Hb and complete blood count) were obtained by automatic analysis (Cell Counter: Medonic 530, cell counter: Medonic 530; EMerck, Darmstadt, Germany) and Hb variants (HbA, HbF and HbA 2 /E) were estimated by high performance liquid chromatography (HPLC) (Bio-Rad Lab., Hercules, CA, USA) using manufacturer's protocol. DNA was isolated from white blood cells, using a DNA isolation kit for mammalian blood (Qiagen, Venlo, The Netherlands). Patients were screened for five common b-thalassemia mutations of Eastern India 5-7 like IVS1-1 (G-T), IVS1-5 (G-C), codon 8/9 (+G), codon 26 (G-A), and Fr. 41/42 (−TCTT). The screening was performed by polymerase chain reaction (PCR) based technique, amplification refractory mutation system (ARMS) as described by Old. phate was done to deplete the high abundant proteins from the plasma fraction as described in our earlier work. 9 The depleted plasma fraction was then dialyzed against 10 mM Tris, 5 mM KCl, pH 7.5, at 4°C, which was then used for 2D gel experiments. The protein sample was then separated by 2D gel electrophoresis (Bio-Rad) and the gels were stained following the protocol as described in our earlier work and densitometry analysis done using the PDQuest (V 7.1) software package (Bio-Rad).
Results and Discussion

Mutational studies
The clinical features of the family members are given in Table 1 . The HPLC results indicate that the father (P1), the younger son (P4) and the non-related sample P5 are HbE-b-thalassemics and the mother (P2) and the elder son (P3) are HbEE. These data were recon- P2 and P3 are homozygous for HbE, hence no other b mutations were found in them, which confirm their homozygous state of HbE. P1 and P4 have another b mutation IVS 1-5 (G-C) along with Cod 26 (G-A), responsible for making them compound heterozygous i.e. HbE-b-thalassemia. These mutational studies also confirm that, P4, who is the main concern of this study, inherits HbE [Cod 26 (G-A)] allele from mother (P2) and other mutated b [IVS 1-5 (G-C)] allele from father (P1) (Figure 1 ).
Differences in the fractionated plasma proteome
On comparing the normalized intensities of Laboratory study Figure 2 ). Transferrin (Q53H26) and plasminogen (Q5TEH4) show down regulation in the P1, P4 and P5. The extent of down regulation is lesser in P5, which could be attributed to the presence of very high level of HbF (33%). 12 The lowering of the transferrin levels could be due to iron overload, commonly resulting from frequent blood transfusion. 13 Plasminogen is an inactive precursor of plasmin, and is involved in fibrinolysis. Chronic hypercoagulable state is observed in thalassemic patients undergoing regular transfusion, like in case of P4. Lowering of the plasminogen level could be a manifestation of this state.
14 Since father does not take any transfusion, we can only assume that the decrease in plasminogen in father is due to the maintenance of homeostasis from oxidative stress produced in the blood.
The haptoglobin precursor (HPHU2) and adenylate kinase 1 (Q5T9B7_HUMAN) are the two proteins, which is seen to be down regulated only in P4 and P5 as compared to normal. In this case, haptoglobin precursor (HPHU2) can be explained in the same light as haptoglobin precursor (HPHU1). Adenylate kinase 1 in plasma has been reported to play a role in the irreversible breakdown of any adenosine diphosphate (ADP) accessible to it. The aggregation of platelets by ADP, in turn is thought to play a role in homeostasis and thrombosis. It is inferred that degradation of ADP leads to the reversal of aggregation. Hence the down regulation of adenylate kinase 1 is seen in case of the transfusion dependent patients, who are prone to thrombolytic events. 15 As shown in earlier work, 4 redox regulator proteins like, peroxiredoxin 2 (prdx2), thioredoxin, Cu-Zn superoxide dismutase and chaperones like hsp70 and a hemoglobin stabilizing protein show marked increase in erythrocyte cytosol and the extent of increase depends on the extent of HbE percentage present in the samples. It is seen in our earlier proteomic study 4 that patients having HbE levels ranging in between 50-60% show higher changes in these proteins compared to those with >80% HbE, as observed here in case of P1 with 83.2% HbE.
To summaries, we have seen that the genomics study of the family showed that P1 and P4 has the exactly identical mutation in their b globin gene, but the father showed no clinical manifestation, whereas the younger son is severely anemic and requires blood transfusion every month. Proteomic study revealed that few plasma proteins, involved in hemoglobin scavenging, hemolysis or hypercoagulation show differential changes between the strongly transfusion dependent patients, P4 and P5 from those of normal individuals and the ones who do not need blood transfusions, P1, P2 and P3 indicating the changes to be specific to the disease conditions. Erythrocytes from the P4 and P5 undergo oxidative stress, are prone to hemolysis and found to have tendencies of hypercoagulation. Taken together, this report shows the importance of differential protein expressions in the clinical presentation of the disease as well as the modulators of globin synthesis. 16 The combination of both genomic and proteomic approaches could provide a better understanding of the disease progression and pathophysiology.
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Introduction
Blood plasma is a rich source of biochemical products that can indicate physiological or clinical status of a patient [1] . It is the most valuable specimen for protein biomarker determination because it is readily obtainable and contains thousands of protein species secreted from cells and tissues [2, 3] . The discovery of protein biomarkers in plasma for diseases is challenging and requires a highly parallel display and quantization strategy for proteins [4] [5] [6] like two dimensional gel electrophoresis (2DGE). The protein content of serum however, is dominated by a handful of proteins such as albumin, immunoglobulins (IgG), and lipoproteins present across an extraordinary dynamic range of concentration. This exceeds the analytical capabilities of traditional proteomic methods, making detection of lower abundance serum proteins extremely challenging. Reduction of sample complexity is thus an essential first step in the analysis of plasma proteome [7] .
There have been three main methods of depleting abundant proteins from serum samples: affinity removal method [1, 4, [8] [9] [10] ; membrane filtration method to separate low-mass proteins from high-mass ones [7] ; and multidimensional chromatographic fractionation [3, 4, 6] . But all these methods are expensive, laborious and time-consuming, as depletion of multiple abundant proteins from each plasma sample requires multiple technical steps. Besides, all these studies were mainly concentrated on the depletion of high-abundance proteins, primarily albumin and IgG, with little attention to detection of low-abundance biomarker proteins. We have employed 20% ammonium sulphate precipitation for rapid depletion of abundant proteins from plasma. Fountoulakis and coworkers have earlier reported fractionation of plasma proteins with 50% and 70% ammonium sulphate to reduce concentrations of high-abundance components and enrich lower abundant components in plasma 2D profiles, thereby facilitating the identification of disease markers [11] . Unlike other albumindepletion studies, we checked the efficiency of our method in detecting differentially regulated plasma proteins in hematological malignancies like B-cell acute lymphoblastic leukemia (B-ALL), acute myeloid leukemia (AML) and in the hemoglobinopathy, HbEβ−thalassemia.
We could detect differential regulation of several proteins in leukemic and thalassemic plasma samples compared to normal controls which includes many differentially regulated proteins in leukemic plasma samples also identified earlier.
Materials and Methods
Fractionation of plasma proteins using ammonium sulphate
Blood plasma samples of healthy normal volunteers, and B-ALL, AML and HbEβ-thalassemia patients on de novo diagnosis, were collected from R.K. Mission Hospital and Clinical Hematology Service, Kolkata. Clinical details of normal individuals and patients are summarized in Supplementary material 1. Written consent was obtained from all of the participants, and the study was conducted in accordance with the principles of the Helsinki Declaration with the approval of the institutional ethics committee. Complete protease inhibitor cocktail (Roche Diagnostics, Germany) was added whenever plasma was stored at -80°C for later use. Plasma samples were centrifuged at 12000 g, 4°C, for 30 minutes, and the supernatants diluted with PBS (2.7 mM KCl, 1.5 mM KH 2 PO 4 , 137 mM NaCl, 8.1 mM Na 2 HPO 4 , pH 7.4) to protein concentrations ~20 mg/ml. Diluted plasma samples were distributed into 1 ml aliquots. Next, 55, 113, 144, 176, 208, 242, 277, 314, and 351 milligrams of (NH 4 ) 2 SO 4 were added to different aliquots for attaining 10%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, and 55% salt concentrations respectively, and incubated on ice for
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30 minutes with occasional mixing. The solutions were centrifuged at 12000 g, 4°C for 25 minutes, the supernatants taken in fresh tubes and the precipitate dissolved in minimum volume of solubilization buffer (5 mM sodium phosphate, 20 mM KCl, 1 mM EDTA, 0.2 mM DTT, and pH-8.0). The starting plasma, the supernatant and the solubilized ammonium sulphate precipitate, all three were dialysed overnight against 10 mM Tris, 5 mM KCl, pH-7.5, at 4°C.
Two dimensional gel electrophoresis and image analysis
After dialysis, the starting plasma, the supernatant and the solubilized ammonium sulphate precipitate, all three were mixed with equal volume of 2D sample buffer containing 8 M urea, 2% (w/v) CHAPS, 0.05% Bio-lyte 3-10 ampholyte, 20 mM DTT (BioRad, Hercules, CA) and Protease inhibitor (Roche Diagnostics). The protein concentrations of the samples were estimated using RC DC protein estimation kit (Bio-Rad), and an absolute amount of 1.8 mg for Coomassie staining, or 600 μg for silver staining, or 1.2 mg for SYPRO RUBY staining, was taken in a final volume of 350 μl. 17 cm pH 3-10 IPG strips (Bio-Rad) were passively rehydrated or cup-loaded with the plasma samples. IEF was carried out in a Protean IEF cell (BioRad), stepwise up to 120000 Volt-Hours. Equilibration of the strips post IEF was performed following published protocol [12] . The second dimension was run on 8-16% polyacrylamide gradient gels in a Protean II XL electrophoresis module (Bio-Rad). Gels were stained either with Blue Silver Coomassie [13] or SYPRO-RUBY (Sigma) according to manufacturer's instructions, or Silver stain according to the method of Rabilloud [14] . Image captures and analyses were done on Versa Doc series 3000 imaging system using PDQuest software (version 7.1, BioRad). Densitometry analysis of the gel spots of interest was performed using the density tool of PDQuest. Spot volume (intensity) of the desired spot(s) was normalized as parts per million (ppm) of the total spot volume using the spots that were present in all gels, to calculate the relative abundance of a spot in a sample.
In-gel tryptic digestion and mass spectrometry
Sequencing grade trypsin was purchased from Promega (Madison, WI). All other reagents were purchased from Pierce (Rockford, USA). The protein spots from Coomassie and SYPRO-RUBY stained 2D gels of normal plasma were excised using a robotic spot-cutter (Bio-Rad). The gel pieces were de-stained with 50% acetonitrile, 25 mM ammoniun bicarbonate. Subsequent in-gel tryptic digestion, peptide elution, acquisition of MS and MS/MS spectra and database searches were done following our published protocol [15] . Recrystallized CHCA and 2, 5-DHB (Sigma) were used as matrices. MS of the digested peptides was done in positive reflector mode in a MALDI-TOF/TOF tandem mass spectrometer (Applied Biosystems, AB 4700). Autotryptic and common keratin peaks were validated and subsequently excluded from MS/MS analysis. Twelve most intense peptides from each spot were subjected to MS/MS analysis. Peak lists were prepared from MS and MS/MS data using GPS explorer V3.6 (Applied Biosystems) software and noise reduction and de-isotoping were performed using default settings. Resulting PMF and MS/MS data were searched against human MSDB and Swiss-Prot databases using in-house MASCOT V2.1 (Matrix Science, UK) server and MOWSE score (with p<0.05) was considered to determine significant hits. For homologous proteins having similar MOWSE scores, preference was given to the protein with best match between theoretical and experimental molecular weight and pI. All MS experiments were repeated at least thrice, with spots excised from three separate gels. The database search parameters included one missed cleavage, error tolerance of ± 100 ppm for PMF and ± 1.2 Da for MS/MS ion search and variable modifications like carbamidomethyl cysteine, methionine oxidation, and N-terminal acetylation.
Western immunoblotting
Plasma protein samples (25 µg) were re-suspended in 30 µL SDS-PAGE buffer (2% mercaptoethanol (v/v), 1% SDS, 12% glycerol, 50 mM Tris-HCl and a trace amount of bromophenol blue), heated at 95°C for 5 min, cooled and loaded directly onto 12% gel. 1D-SDS-PAGE was performed in a Mini Protean III-cell (Bio-Rad) using Tris-glycine with 0.1% SDS, following manufacturer's instructions. Proteins separated on gel were blotted onto PVDF membranes and subsequently blocked with Tris-buffer-saline (TBS), 5% non fat dry milk for 2h at room temperature. Primary antibodies (Abcam) were diluted in TBS/0.1% Tween (TBST) following manufacturer's protocol. β-Tubulin was used as loading control. Anti-rabbit or anti-mouse HRP-conjugated IgGs were used as secondary antibodies (Abcam). Membranes were washed with TBST and detected by ECL (Pierce) with either the VersaDoc imager (BioRad) or on X-ray film development.
Results
Separation of pre-fractionated plasma proteins using 2DGE
1D-SDS-PAGE profiles of raw plasma, sub-fractions after (NH 4 ) 2 SO 4 precipitations and respective supernatants showed more number of protein bands only in sub-fractions after 20% and 45% (NH 4 ) 2 SO 4 precipitations (Supplementary material 2) . We've chosen the sub-fraction after 20% (NH 4 ) 2 SO 4 precipitation for further 2DGE analysis, which appeared to precipitate the maximum proportion of lower abundance proteins leaving most of the abundant proteins in solution. From 20 mg protein in raw plasma, 3.5 ± 0.8 mg was obtained in the 20% (NH 4 ) 2 SO 4 precipitate while the supernatant retained the rest of it (15 ± 1.6 mg estimated). Both 1D and 2D profiles of raw diluted plasma, the fraction after 20% (NH 4 ) 2 SO 4 precipitation and the supernatant after precipitation together revealed that (NH 4 ) 2 SO 4 precipitates only a fraction of the whole plasma proteome. The particular fraction contained reduced load of abundant plasma proteins and was enriched with various minor proteins leaving the gel electrophoresis profile of the supernatant almost identical to that of raw plasma (Figure 1) . The 1D-SDS-PAGE showed depletion of abundant proteins like albumin and IgG and enrichment/appearance of several lowabundance proteins including a tissue leakage protein, α-fetoprotein in the precipitated fraction ( Figure 1A) . The high percentage of albumin was found to be depleted (>80%) ensuring resolution of other proteins that were obscured by albumin in 2D gels, and minor proteins that were initially hidden by co-migration with albumin or smears became visible ( Figures 1B-1D ). The number of spots visible in 2D gels was doubled from 348 in raw plasma to 617 in the fraction precipitated by 20% (NH 4 ) 2 SO 4 with various new spots appearing in the pI region 4.5-6.5 and between 10 kDa and 50 kDa molecular mass ( Figure 1E ).
We compared the 2DGE profiles of the fraction precipitated by 20% (NH 4 ) 2 SO 4 and the albumin-depleted plasma after treatment with commercially available albumin depletion kit (ProteoPrep Blue Albumin & IgG Depletion kit, Sigma, St.Louis, MO). Supplementary material 3 provides the 2D gel images that shows better performance 20% (NH 4 ) 2 SO 4 to justify the choice of conventional salting-out for enrichment of minor proteins in addition to depletion of abundant proteins from plasma, and preliminary screening of clinical samples. Although the ProteoPrep Blue Albumin and IgG Depletion kit specifically depleted albumin and IgG, the number of spots visible upon albumin-depletion did not increase appreciably as seen from the 2DGE profile.
Identification of plasma proteins by tandem mass spectrometry
Post (NH 4 ) 2 SO 4 precipitation based pre-fractionation, a total of 87 proteins were identified from coomassie and SYPRO-RUBY stained 2D gels of normal plasma, by performing combined searches (MS + MS/MS) against MSDB, NCBI, Swissprot databases, as shown in Figure  2 and elaborated in Table 1 . Of these 64 had significant scores (p ≤ 0.05) in the combined searches. Many of the rest 24 protein identifications were supported by either the published SWISS-2D-PAGE map of human plasma (marked with asterisk ' * ' in Table 1 ), or ion score ≥ 20 of at least one MS/MS fragment, or other proteomic studies of blood plasma/serum [4, 6, 7] (marked with ' * * '). The list included many low abundance proteins that were undetectable in normal plasma prior to (NH 4 ) 2 SO 4 precipitation. Low-abundance proteins present in amounts five to nine orders of magnitude lower than albumin, like precipitation, separated on 2D gels. This reflects a significant gain in the dynamic range of plasma proteins visualized in 2-D gels following 20% (NH 4 ) 2 SO 4 precipitation. We could detect and identify some important blood plasma constituents, like fibrinogen-γ chain and immunoglobulin λ-light chain, that were absent from Anderson and co-workers' report of an exhaustive list of proteins detected and/or identified in plasma [16] . All the 87 proteins were searched for their molecular function, biological process and localization in the PANTHER classification system database17 indicating the identified proteins to be involved in multiple biological processes like blood coagulation, cargo transport, proteolysis, signal transduction, cell-adhesion, immunity/defense, etc.
Display of differentially regulated proteins in patient plasma
The clinical features of the B-ALL, AML, HbEβ-thalassemia patients and the normal controls are summarized in Supplementary material 1. As shown in Figure 3 , a comparison between the fraction of raw plasma proteome fraction after 20% (NH 4 ) 2 SO 4 precipitation, obtained from normal, B-ALL, AML and HbEβ-thalassemia samples revealed ~20 differentially regulated proteins. Differences in mean ppm spot volumes between normal controls and patient samples for all protein spots were subjected to unpaired two-tail student's t-test. Due to the inherent complexity of a 2D gel-based proteomic studies, we have only concentrated on the spots which were significantly different (p ≤ 0.01) between normal and patient plasma sub-proteomes. We observed down-regulation of transferrin, albumin, immunoglobulin heavy chains, apolipoprotein A1 (Apo-A1), transthyretin, α1-B-glycoprotein, α2-HS-glycoprotein (AHSG); and up-regulation of α1-antitrypsin, haptoglobin, interferon-β (INF-β), glutathione-s-transferase (GST), SET domain bifurcated (SETDB), adenylate kinase-1 (AK-1), T-cell receptor-β (TCR-β) in the plasma of B-ALL patients as compared to normal plasma; shown as histogram plots in Figure 4 . 2D profiles of samples from AML (hatched bars in Figure 4 ) and HbEβ-thalassemia (hollow bars in Figure 4 ) patient plasmas indicated opposite trend of differential regulation of most of these proteins, pointing towards the specificity of the observations.
Validation by western immunoblotting
To confirm the results obtained from 2DGE experiments, we quantitated the amounts of four differentially regulated proteins in raw plasma, obtained from a separate set of 3 normal controls and 4 B-ALL patients, using western immunoblotting. Supplementary material 4 shows the immunoblots for 5 proteins with β-tubulin as loading control, and histogram plot of the band intensities. All data were subjected to unpaired two-tail student's t-test and the changes were found to be significant (p≤0.05). The immunoblots clearly supported results from 2DGE experiments. The four proteins: transferrin, α1-antitrypsin, Apo-A1 and albumin, were chosen as representatives for proteolysis-modulating, carrier and acute phase proteins exhibiting differential regulation in B-ALL plasma 2D profiles.
Discussion
Since proteins differ markedly in their solubility at high ionic strength, salting-out has been the most efficient, time-tested and useful procedure for protein enrichment. The advantage of (NH 4 ) 2 SO 4 is its high water-solubility leading to high ionic strength, and low heat of solvation protecting most proteins from denaturation [17] . This simple inexpensive fractionation of plasma proteins with depletes most of the high-abundance proteins e.g. albumin leading to an increase in lowabundance components, as also observed earlier [11] . As evident in this study, 20% (NH 4 ) 2 SO 4 precipitation led to a representative fraction of the plasma proteome effectively facilitating detection of differentiallyregulated protein markers in patient plasma samples with identification of several low-abundance proteins. The composition of the plasma proteome fraction after 20% (NH 4 ) 2 SO 4 precipitation depends primarily on the quantity and solubility of the constituent proteins initially present in the sample, irrespective of the source or nature of the starting material. The fact that (NH 4 ) 2 SO 4 does not differentially deplete plasma proteins from sample to sample has been apparent from the immunoblots of raw undepleted plasma samples, shown in Supplementary material 4. Our investigation of differential regulations in two different-lineage hematological malignancies, i.e. ALL & AML, and an unrelated blood disorder with similar symptoms viz. HbEβ-thalassemia, establishes the specificity of the observed de-regulations with respect to the disease. The specificity of the observations adds an extra line of evidence to the suitability of 20% (NH 4 ) 2 SO 4 precipitation for detection of disease biomarkers in patient plasma samples. Immunoaffinity-based chromatography effectively depletes high-abundance proteins from the plasma, but even these expensive, laborious and time consuming commercially available methods fail to completely remove high-abundance components and suffer from their own limitations of specificity [18] [19] [20] [21] . Our approach has been to use a simple, cost-effective method to obtain plasma fractions with reduced content of abundant proteins and maximum number of wellresolved spots on 2D gels. Although (NH 4 ) 2 SO 4 fractionation does not specifically deplete or remove a particular protein or class of proteins, however, it also does not show preference towards a particular protein mixture, irrespective of sample type (normal or patient). It treats two different types of body fluid samples e.g. plasma & urine, differently, but remains unbiased towards the source e.g. from patients or from normal volunteers. Thus, it could be effectively used for differential proteomics in clinical studies. Use of combinatorial peptide ligand libraries for depletion of abundant proteins and accessing lowabundance biomarkers in clinical proteomics studies of blood plasma [22] [23] [24] further supports our notion that any pre-fractionation strategy for plasma could come handy to increased access to disease-markers apart from depletion of high abundance components.
Many of our observations in disease plasma were supported by earlier reports. Haptoglobin up-regulation in AML, CML, and multiple myeloma has also been reported in earlier studies [25] [26] [27] . While 2D profiles support the up-regulation of haptoglobin β-chain in AML plasma [26] , we emphasize on haptoglobin α-chain that exhibits opposite trends of de-regulation in AML/HbEβ-thalassemia and B-ALL. This further highlights the application of (NH 4 ) 2 SO 4 precipitation for preliminary screening of patient plasma samples. AHSG is reported to be down-regulated in AML, ALL, NHL and multiple myeloma patients [25, 26, 28] . We observed down-regulation of AHSG in B-ALL plasma in contrast to an up-regulation in AML/ HbEβ-thalassemia plasma (Figure 4 ). Since lymphoblasts fail to mature into antibody-secreting plasma cells in B-ALL, the patients show significant down-regulation of immunoglobulin heavy chains in plasma. In contrast, immunoglobulin heavy chains are up-regulated in AML/HbEβ-thalassemia patient sera [26] . Additionally, Apo-A1 is down-regulated in B-ALL plasma contrary to the observation in AML (Figure 4) . Hence IgG and Apo-A1 can serve as important biomarkers of B-ALL. Up-regulation of transferrin, AHSG and AK-1, vs. downregulation of transthyretin, Apo-A1, Apo-E and TCR-β in HbEβ-thalassemia plasma, compared to normal controls, are all preliminary reports that warrant further investigations with increased sample size. As most of the de-regulated proteins participate in multiple physiological processes like proteolysis, cargo-transport and iron homeostasis, their de-regulation might enlighten clinical manifestation of the disease. The western immunoblots qualitatively supported the 2DGE results but showed quantitative discrepancies in the degrees of deregulation of the proteins, most likely attributable to differences in the protein loads and detection limits of the two techniques. Moreover, immunoblot confirmation using a separate set of B-ALL patients and normal controls further emphasizes on the prospects of the reported de-regulations as potential diagnostic and prognostic indicators of the respective diseases, and that the differences do not arise out of the plasma pre-fractionation technique used. In conclusion, 20% ammonium sulphate precipitation shows prospects of accelerating the preliminary screening and detection of disease biomarkers in blood plasma. We further emphasize upon the assets of proteomic studies over single protein detection assays in revealing differential regulation of different classes of proteins, simultaneously in a disease, which might be a step ahead in cutting through the complexity diseases and explaining their pathophysiology and clinical manifestation. This study also reports for the first time a 2DGE based proteomic investigation of B-ALL and HbEβ-thalassemia.
